Recent Progress in the Vaccine Development Against Epstein-Barr Virus

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Epstein-Barr virus (EBV) is a globally prevalent human herpesvirus, with latent infection in ~95% of adults.
• EBV is linked to significant diseases, including cancers and neurological disorders, underscoring the need for vaccines.
• Current EBV vaccine development is a priority due to the substantial disease burden.

Purpose of the Study:

• To review current understanding of EBV biology and pathogenesis.
• To identify key viral antigens as potential vaccine targets.
• To summarize advances in various EBV vaccine platforms and their preclinical/clinical evidence.

Main Methods:

• Review of existing literature on EBV biology, pathogenesis, and immune evasion.
• Analysis of viral antigens (gp350, gp42, gH/gL, latency proteins) for vaccine potential.
• Summary of diverse vaccine platforms: subunit, viral vector, nanoparticle, and mRNA.

Main Results:

• EBV's biological structure and immune evasion mechanisms are detailed.
• Key viral antigens are identified as promising targets for vaccine design.
• Various vaccine platforms show preclinical and clinical promise, though none are approved.

Conclusions:

• The review provides a comprehensive overview of the current EBV vaccine research landscape.
• It highlights the potential of multiple vaccine platforms and targets for future development.
• Further research is needed to bring an effective EBV vaccine to clinical use.